Covid-19 roundup: Germany pours nearly $450M into BioNTech; AstraZeneca still hasn't resumed its vaccine trial in the US
Pfizer CEO Albert Bourla has made a point since the pandemic’s early days of rejecting US assistance for their Covid-19 vaccine, separating them from the rest of the big players and casting the old pharma giant as a dynamic company that could move better and faster alone.
The story, though, for their German biotech partner BioNTech — the company whose mRNA technology is actually behind their vaccine — is a little different. In June, the European Investment Bank gave BioNTech €100 million debt financing to support manufacturing and development.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
